SEC Comment Letter for Phio Pharmaceuticals Corp. (PHIO) (CIK 0001533040) (PHIO) — May 16, 2018

Phio Pharmaceuticals Corp. (PHIO) (CIK 0001533040)
Date: May 16, 2018 · CIK: 0001533040 · Accession: 0000000000-18-015212

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-224799

Date

May 16, 2018

Author

President

Form

UPLOAD

Company

Phio Pharmaceuticals Corp. (PHIO) (CIK 0001533040)

Letter

May 16, 2018 Geert Cauwenbergh President RXi Pharmaceuticals Corporation 257 Simarano Drive, Suite 101 Marlborough, Massachusetts 01752 Re:RXi Pharmaceuticals Corporation Registration Statement on Form S-1 Filed May 9, 2018 File No. 333-224799 Dear Dr. Cauwenbergh: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Irene Paik at 202-551-6553 with any questions. Division of Corporation Finance Office of Healthcare & Insurance cc: Ryan A. Murr - Gibson, Dunn & Crutcher LLP

Show Raw Text

May 16, 2018
Geert Cauwenbergh
President
RXi Pharmaceuticals Corporation
257 Simarano Drive, Suite 101
Marlborough, Massachusetts 01752
Re:RXi Pharmaceuticals Corporation
Registration Statement on Form S-1
Filed May 9, 2018
File No. 333-224799
Dear Dr. Cauwenbergh:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Irene Paik at 202-551-6553 with any questions.
Division of Corporation Finance
Office of Healthcare & Insurance
cc:       Ryan A. Murr - Gibson, Dunn & Crutcher LLP

SecProbe.io